A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
Status:
Completed
Trial end date:
2017-10-19
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up
to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in
participants with severe postpartum depression (PPD) compared to placebo injection as
assessed by the change from baseline in Hamilton Rating Scale for Depression (HAM-D) total
score.